Dr. Marc Girard on the Science of Vaccination
Marc Girard M.D., M.Sc.
Marc Girard was qualified in veterinary medicine in 1960 at the University of Paris, and in Science in 1967, and was trained in molecular biology of poliovirus as a post-doctoral fellow in the USA and France. His focus then changed to HIV where he spent 20 years working on the development of an vaccine. He served as Chairman, Department of Virology, Institut Pasteur, Paris from 1997 to 1999, as Director, European Research Center for Virology and Immunology, France from 1999 to 2001. Chairman, European Consortium for HIV Vaccine (EuroVac), Brussels from 1999 to 2002. Was Director General of the Merieux Foundation from 2001 to 2003. He served as the Chief Scientific Officer of Pasteur-Mérieux Sérums et Vaccins now known as Sanofi-Pasteur.
He retired in 2004 but still consults for WHO, pharmaceutical industry and vaccine manufacturers. He was the head of Vaccine Development of Mymetics Corp. from January 15, 2004 to March 9, 2009
Girard still teaches and is a member of the French National Academy of Medicine.
** It would be difficult to say that Marc Girard is not qualified to comment on issues surrounding vaccine safety and effectiveness.
Comments and papers regarding vaccines.
In effect, if this is so easy for amateurs to get involved in vaccine controversies, this is because as a whole, the development, assessment and administration of these agents is a shame for the medical world: the weaknesses, contradictions, dissimulations and even lies of most vaccine leaders or governmental “experts” are so gross that they cannot escape the attention even of non medically-trained persons.
Maglione MA. Pediatrics. 2014. (Go to comments at bottom of page for all of Marc’s scathing critique.)
By the distance between what it demonstrates and what it claims, this paper (as well as the preceding IOM report this one is supposed to update) illustrates that the issue of vaccines safety is still a matter of serious concern for anyone endowed with a minimum of expertise in drug safety or pharmacoepidemiology.